Tandem Diabetes Care Inc [TNDM] stock is trading at $19.17, up 5.45%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The TNDM shares have gain 6.74% over the last week, with a monthly amount drifted -41.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Tandem Diabetes Care Inc [NASDAQ: TNDM] stock has seen the most recent analyst activity on March 05, 2025, when Morgan Stanley downgraded its rating to a Equal-Weight and also revised its price target to $22 from $45. Previously, Citigroup downgraded its rating to Neutral on March 04, 2025, and dropped its price target to $24. On March 03, 2025, downgrade downgraded it’s rating to Equal Weight and revised its price target to $22 on the stock. Bernstein downgraded its rating to a Mkt Perform and decreased its price target to $25 on February 28, 2025. Morgan Stanley upgraded its rating to a Overweight but $45 remained the price target by the analyst firm on December 02, 2024. Bernstein started tracking with a Outperform rating for this stock on November 06, 2024, and assigned it a price target of $42. In a note dated October 04, 2024, Goldman initiated an Neutral rating and provided a target price of $46 on this stock.
Tandem Diabetes Care Inc [TNDM] stock has fluctuated between $17.64 and $53.69 over the past year. Currently, Wall Street analysts expect the stock to reach $41.33 within the next 12 months. Tandem Diabetes Care Inc [NASDAQ: TNDM] shares were valued at $19.17 at the most recent close of the market. An investor can expect a potential return of 115.6% based on the average TNDM price forecast.
Analyzing the TNDM fundamentals
Tandem Diabetes Care Inc [NASDAQ:TNDM] reported sales of 940.20M for the trailing twelve months, which represents a growth of 43.62%. Gross Profit Margin for this corporation currently stands at 0.46% with Operating Profit Margin at -0.09%, Pretax Profit Margin comes in at -0.09%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.1, Equity is -0.39 and Total Capital is -0.14. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.8.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.61 points at the first support level, and at 18.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.50, and for the 2nd resistance point, it is at 19.84.
Ratios To Look Out For
For context, Tandem Diabetes Care Inc’s Current Ratio is 2.93. As well, the Quick Ratio is 2.33, while the Cash Ratio is 0.28. Considering the valuation of this stock, the price to sales ratio is 1.36, the price to book ratio is 4.83.
Transactions by insiders
Recent insider trading involved Kyrillos Jean-Claude, EVP & Chief Operating Officer, that happened on Mar 07 ’25 when 10538.0 shares were purchased. Director, BLICKENSTAFF KIM D completed a deal on Nov 21 ’24 to sell 30000.0 shares. Meanwhile, Director BLICKENSTAFF KIM D sold 10000.0 shares on Nov 20 ’24.
